View Older Stories View More Recent Stories

Mar 8, 2016 08:04AM Sanofi Pasteur (SNY) and Merck (MRK) to End Joint Vaccines Operations in Europe
Mar 8, 2016 08:00AM Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strateg
Mar 7, 2016 04:30PM Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire
Mar 7, 2016 08:10AM Merck (MRK) Annnounces FDA Acceptance of KEYTRUDA sBLA
Mar 7, 2016 08:00AM FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Mar 4, 2016 10:00AM Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa
Feb 23, 2016 01:30PM Merck Announces Second-Quarter 2016 Dividend
Feb 22, 2016 11:30AM Merck Puts Spotlight on Women's Health and Well-being
Feb 22, 2016 08:07AM Merck (MRK) Announces ISENTRESS Phase 3 Met Primary Efficacy Endpoint in HIV-1
Feb 22, 2016 08:00AM Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase 3 Study
Feb 17, 2016 06:45AM Diplomat Pharmacy (DPLO) Begins Filling Prescriptions for ZEPATIER as HCV Treatment (MRK)
Feb 16, 2016 07:02AM Merck (MRK) Announces Receipt of CRL for ZETIA and VYTORIN NDA
Feb 15, 2016 05:30PM Merck Receives Complete Response Letter from the U.S. FDA for ZETIA® (ezetimibe) and VYTORIN® (ezetimibe and simvastatin)
Feb 4, 2016 08:00AM FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving
Feb 3, 2016 06:45AM Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
Jan 29, 2016 06:18AM Merck (MRK) Announces FDA Approval of ZEPATIER as Genotype 1, 4 HCV Treatment
Jan 28, 2016 07:01PM Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Jan 28, 2016 06:59PM Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Jan 27, 2016 08:31AM Merck (MRK) Announces FDA Acceptance of Bezlotoxumab BLA in C. difficile Prevention
Jan 27, 2016 08:30AM Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence
Jan 25, 2016 09:32AM Pre-Open Stock Movers 01/25: (AFMD) (GRUB) (SUNE) (TYC) Higher; (OMED) (NVAX) (TWTR) Lower (more...)
Jan 19, 2016 10:00AM Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium
Jan 15, 2016 07:00AM Merck (MRK) Announces Resolation to Vioxx Securities Class Action; Will Pay $830M
Jan 15, 2016 07:00AM Merck Resolves Previously Disclosed Securities Class Action Lawsuit Related to Vioxx
Jan 11, 2016 04:08PM Merck (MRK) Announces Acquisition of IOmet
Jan 11, 2016 04:08PM Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program
Jan 8, 2016 08:00AM Merck to Present at the 34th Annual J.P. Morgan Healthcare Conference
Jan 5, 2016 08:00AM Merck to Hold Fourth-Quarter and Full-Year 2015 Sales and Earnings Conference Call on February 3
Jan 4, 2016 08:00AM Merck to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
Dec 23, 2015 08:34AM Merck (MRK) Announces WHO Acceptance of EUAL for Ebola Zaire Vaccine
Dec 23, 2015 08:30AM World Health Organization to Review Merck’s Investigational Ebola Vaccine for Emergency Use Assessment and Listing
Dec 19, 2015 10:55AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
Dec 18, 2015 04:06PM Merck (MRK) Announces Expanded Indication for KEYTRUDA
Dec 18, 2015 04:05PM FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
Dec 18, 2015 08:04AM Merck's (MRK) Elbasvir/Grazoprevir MAA Will New Come Under EMA CHMP Standard Review
Dec 18, 2015 08:00AM Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir
Dec 15, 2015 05:09PM Merck (MRK) Says GARDASIL 9 Age Expanded in Males 16-26
Dec 15, 2015 05:07PM FDA Approves Expanded Age Indication for GARDASIL® 9 in Males
Dec 10, 2015 09:00AM Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG and Merck's Checkpoint Inhibitor Keytruda in Patients with Non-Small Cell Lung Cancer
Dec 10, 2015 06:31AM Eli Lilly & Co. (LLY), Merck (MRK) Enter Collaboration for Abemaciclib Phase 1
Dec 10, 2015 06:30AM Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® Combination Trial
Dec 8, 2015 08:06AM Merck (MRK) Presents KEYTRUDA Data at ASH 2015
Dec 8, 2015 08:00AM Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA® (pembrolizumab) Data
Dec 7, 2015 08:03AM Merck (MRK) Announces Receipt of RENFLEXIS Approval in Korea
Dec 7, 2015 08:00AM Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS™ (Infliximab), a Biosimilar of Remicade, in Korea
Dec 7, 2015 07:00AM Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA® (pembrolizumab) Combined With Lenalidomide and Dexamethasone
Dec 4, 2015 08:01AM Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma
Nov 30, 2015 08:30AM New Survey Showed That Most People Living With HIV Were More Concerned About Their Other Chronic Health Conditions Than Their HIV
Nov 24, 2015 12:35PM Merck Announces Increased Quarterly Dividend
Nov 21, 2015 04:30PM Merck Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Con
View More Recent Stories View Older Stories